Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-06-05 00:00:00 ET · period of report 2024-06-03 · accession 0001601830-24-000073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-05 | 2024-06-03 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +13.1K | 69.4K | +23% | $0 |
| D | 2024-06-05 | 2024-06-03 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +26.2K | 26.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-06-03 | A | A | 13,097 | $0.00 | 69,411 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-06-03 | A | A | 26,193 | $0.00 | 26,193 | D | $8.59 · — to 2034-06-03 | 26,193 Class A Common Stock | (F2) The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. |